{"id":37319,"date":"2025-07-15T14:54:49","date_gmt":"2025-07-15T06:54:49","guid":{"rendered":"https:\/\/flcube.com\/?p=37319"},"modified":"2025-07-15T14:54:50","modified_gmt":"2025-07-15T06:54:50","slug":"sichuan-biokins-iza-bren-approved-for-phase-ii-clinical-study-in-renal-cell-carcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37319","title":{"rendered":"Sichuan Biokin&#8217;s Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma"},"content":{"rendered":"\n<p>China&#8217;s Sichuan Biokin Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 688506<\/a>) has received approval from the National Medical Products Administration (NMPA) to carry out a Phase II clinical study for its novel EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC) iza-bren (BL-B01D1). The study will evaluate the efficacy and safety of iza-bren combined with lenvatinib \u00b1 pembrolizumab in advanced renal cell carcinoma (RCC).<\/p>\n\n\n\n<p><strong>Iza-bren: A First-in-Class Bispecific ADC<\/strong><br>Iza-bren represents a significant innovation in the field of oncology as a first-in-class EGFR\u00d7HER3 bispecific ADC. This novel therapeutic approach is designed to target cancer cells with precision, enhancing treatment outcomes for patients with advanced RCC.<\/p>\n\n\n\n<p><strong>Global Clinical Development<\/strong><br>The drug is currently the subject of over 40 clinical trials across China and the U.S. for multiple tumor types. The most advanced program has reached Phase III, underscoring the potential of iza-bren to address significant unmet medical needs in oncology.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/688506_20250715_JH80.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688506_20250715_JH80.\"><\/object><a id=\"wp-block-file--media-1fc9690e-34b9-4eca-9391-200d2a67038e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/688506_20250715_JH80.pdf\">688506_20250715_JH80<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/688506_20250715_JH80.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1fc9690e-34b9-4eca-9391-200d2a67038e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37321,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,151,62,28,857],"class_list":["post-37319","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-clinical-trial-approval-initiation","tag-multi-specific-antibodies","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sichuan Biokin&#039;s Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical Products Administration (NMPA) to carry out a Phase II clinical study for its novel EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC) iza-bren (BL-B01D1). The study will evaluate the efficacy and safety of iza-bren combined with lenvatinib \u00b1 pembrolizumab in advanced renal cell carcinoma (RCC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37319\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Biokin&#039;s Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma\" \/>\n<meta property=\"og:description\" content=\"China&#039;s Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical Products Administration (NMPA) to carry out a Phase II clinical study for its novel EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC) iza-bren (BL-B01D1). The study will evaluate the efficacy and safety of iza-bren combined with lenvatinib \u00b1 pembrolizumab in advanced renal cell carcinoma (RCC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37319\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-15T06:54:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-15T06:54:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1503.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37319#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37319\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Biokin&#8217;s Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma\",\"datePublished\":\"2025-07-15T06:54:49+00:00\",\"dateModified\":\"2025-07-15T06:54:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37319\"},\"wordCount\":164,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37319#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1503.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"Clinical trial approval \\\/ initiation\",\"Multi-specific antibodies\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37319#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37319\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37319\",\"name\":\"Sichuan Biokin's Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37319#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37319#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1503.webp\",\"datePublished\":\"2025-07-15T06:54:49+00:00\",\"dateModified\":\"2025-07-15T06:54:50+00:00\",\"description\":\"China's Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical Products Administration (NMPA) to carry out a Phase II clinical study for its novel EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC) iza-bren (BL-B01D1). The study will evaluate the efficacy and safety of iza-bren combined with lenvatinib \u00b1 pembrolizumab in advanced renal cell carcinoma (RCC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37319#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37319\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37319#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1503.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1503.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sichuan Biokin's Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37319#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Biokin&#8217;s Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Biokin's Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry","description":"China's Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical Products Administration (NMPA) to carry out a Phase II clinical study for its novel EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC) iza-bren (BL-B01D1). The study will evaluate the efficacy and safety of iza-bren combined with lenvatinib \u00b1 pembrolizumab in advanced renal cell carcinoma (RCC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37319","og_locale":"en_US","og_type":"article","og_title":"Sichuan Biokin's Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma","og_description":"China's Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical Products Administration (NMPA) to carry out a Phase II clinical study for its novel EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC) iza-bren (BL-B01D1). The study will evaluate the efficacy and safety of iza-bren combined with lenvatinib \u00b1 pembrolizumab in advanced renal cell carcinoma (RCC).","og_url":"https:\/\/flcube.com\/?p=37319","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-15T06:54:49+00:00","article_modified_time":"2025-07-15T06:54:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1503.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37319#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37319"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Biokin&#8217;s Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma","datePublished":"2025-07-15T06:54:49+00:00","dateModified":"2025-07-15T06:54:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37319"},"wordCount":164,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37319#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1503.webp","keywords":["ADC \/ XDC","Biokin Pharmaceutical","Clinical trial approval \/ initiation","Multi-specific antibodies","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37319#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37319","url":"https:\/\/flcube.com\/?p=37319","name":"Sichuan Biokin's Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37319#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37319#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1503.webp","datePublished":"2025-07-15T06:54:49+00:00","dateModified":"2025-07-15T06:54:50+00:00","description":"China's Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical Products Administration (NMPA) to carry out a Phase II clinical study for its novel EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC) iza-bren (BL-B01D1). The study will evaluate the efficacy and safety of iza-bren combined with lenvatinib \u00b1 pembrolizumab in advanced renal cell carcinoma (RCC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37319#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37319"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37319#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1503.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1503.webp","width":1080,"height":608,"caption":"Sichuan Biokin's Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37319#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Biokin&#8217;s Iza-bren Approved for Phase II Clinical Study in Renal Cell Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1503.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37319"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37319\/revisions"}],"predecessor-version":[{"id":37322,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37319\/revisions\/37322"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37321"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}